



Published in final edited form as:

Clin Cancer Res. 2014 August 15; 20(16): 4200–4209. doi:10.1158/1078-0432.CCR-13-2574.

Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma

Chand Khanna, DVM, PhD,

Dipl ACVIM (Oncology), Molecular Oncology Section – Metastasis Biology, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr., Rm 2144, Bethesda Maryland 20892, 301-594-3406 (Tel), 301-443-1838 (Fax)

Timothy M. Fan, DVM, PhD,

Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois 61802

Richard Gorlick, MD,

Professor of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine of Yeshiva University, Vice Chairman, Division Chief of Hematology/Oncology, Department of Pediatrics, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd Floor, Bronx, New York 10467, Phone # - 718 - 741-2342, Fax # - 718 - 920-6506

Lee J Helman, MD,

Scientific Director for Clinical Research, Center for Cancer Research, NCI, Bld 31 Rm 313A11, Bethesda, MD 20892-2440, Phone 3014964257, helmanl@NIH.gov

Eugenie S. Kleinerman, M.D.,

Professor and Head, Division of Pediatrics, Professor, Department of Cancer Biology, Mosbacher Pediatrics Chair, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit #87, Houston, Texas 77030, (713) 792-8110, Fax: (713) 794-5042

Peter C. Adamson, MD,

Chair, Children's Oncology Group, Chief, Division of Clinical Pharmacology & Therapeutics, The Children's Hospital of Philadelphia, Tel (215) 590-6359, Fax (215) 590-7544, adamson@email.chop.edu, padamson@childrensoncologygroup.org, www.childrensoncologygroup.org <<http://www.childrensoncologygroup.org>>

Peter J. Houghton, Ph.D.,

Center for Childhood Cancer, The Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, Ph. 614 355 2670, Fx. 614 355 2927, Peter.Houghton@nationwidechildrens.org

William D. Tap, MD,

Section Chief, Sarcoma Oncology, Melanoma and Sarcoma Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10065, Tel: 646-888-4163, Fax: 646-888-4252, tapw@mskcc.org

Danny R. Welch, Ph.D.,

Professor & Chair of Cancer Biology, Hall Family Professorship in Molecular Medicine, Kansas Bioscience Authority Eminent Scholar, The Kansas University Medical Center, 3901 Rainbow Blvd. - Wahl Hall West 2003, Mailstop 1071, Kansas City, KS 66160, Lab: 913-945-7797/7798/7799, Fax: 913-588-4701

Patricia S. Steeg, Ph.D.,

Chief, Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Building 37, Room 1126, Bethesda, MD 20892, 301-402-2732, 301-402-8910 (fax)

Glenn Merlino, Ph.D.,

Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Building 37, Room 5002, 37 Convent Drive, Bethesda, MD 20892-4264, USA, 301-496-4270, gmerlino@helix.nih.gov

Poul HB Sorensen, MD, PhD,

Johal Chair in Childhood Cancer Research, Professor, Department of Pathology, University of British Columbia, Senior Scientist, BC Cancer Research Centre, 675 West 10th Avenue, Room 4112, Vancouver, BC, Canada V5Z 1L3, Tel. (604) 675-8202 FAX (604) 675-8218

David G. Kirsch, MD, PhD,

Associate Professor and Vice Chair for Basic & Translational Research of Radiation Oncology, Associate Professor Pharmacology & Cancer Biology, Duke University Medical Center, Box 91006 LSRC B233, Durham, NC 27710, david.kirsch@duke.edu

Katherine A. Janeway, MD, MMSc,

Assistant Professor of Pediatrics, Harvard Medical School, Associate Physician, Pediatric Oncology, Dana Farber Boston Children's Cancer and Blood Disorders Center, 450 Brookline Ave., Boston, MA 02215, Phone: 617-632-4994, kjaneway@partners.org

Brenda Weigel, MD, MSc,

Associate Professor, Division Director Hematology/Oncology, Lehman/Children's Cancer Research Fund Endowed Chair in Pediatric Cancer, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, 366 Mayo Mail Code, (Overnight delivery: 460B CCRB, 425 East River Road), 420 Delaware St. SE, Minneapolis MN 55455, Phone: 612-626-5501, Fax: 612-624-3913

R. Lor Randall, MD, FACS,

The L.B. & Olive S. Young Endowed Chair for Cancer Research, Director, Sarcoma Services & Chief, SARC Lab, Medical Director, HCI Surgical Services, Professor of Orthopaedics, Huntsman Cancer Institute & Primary Children's Medical Center, University of Utah, Lor Randall <Lor.Randall@hci.utah.edu>

Paul Meltzer, M.D., Ph.D.,

Chief, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive MSC 4265, Room 6138, Bethesda, MD 20892-4265, Phone (301) 496-5266, Fax (301) 480-3281, pmeltzer@mail.nih.gov

Stephen J Withrow, D.V.M.,

Stuart Chair in Oncology, Flint Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins CO 80523-1620, Office (970) 297-4175, Fax (970) 297-1254, swithrow@colostate.edu, www.csuanimalcancercenter.org

Melissa Paoloni, DVM,

Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr., Rm 2144, Bethesda Maryland 20892, 301-594-3406 (Tel), 301-443-1838 (Fax)

Rosandra N. Kaplan, MD,

Tumor Microenvironment Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health., 10 Center Drive Bethesda, MD 20817

Beverly A. Teicher, PhD,

Chief, Molecular Pharmacology Branch, National Cancer Institute, 9609 Medical Center Drive, RM 4-W602, MSC 9735, Bethesda, MD 20892, Phone: 240-276-5972, FAX: 240-276-7895, Beverly.Teicher@nih.gov, teicherba@mail.nih.gov

Nita L. Seibel, MD,

Cancer Therapy Evaluations Program, National Cancer Institute, Bethesda, MD, seibelnl@mail.nih.gov

Aykut Üren, M.D.,

Associate Professor, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Department of Oncology, Department of Biochemistry and Molecular & Cellular Biology, Research Building, Room: E312, 3970 Reservoir Road, N.W., Box 571469, Washington, D.C. 20057-1469, phone: 202 687 9504, Fax: 202 687 1434, au26@georgetown.edu

Shreyaskumar R. Patel, MD,

Robert R. Herring Distinguished Professor of Medicine, Center Medical Director, Sarcoma Center, Deputy Chairman, Dept. of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 450/FC 12.3022, Houston, TX 77030, Tel: (713) 792-3626, Fax:(713) 794-1934, spatel@mdanderson.org

Dr. Jeffrey Trent, Ph.D.,

President and Research Director, Translational Genomics Research Institute (TGen), 445 N 5th Street Suite 600, Phoenix, AZ 85004, 602-343-8419, 602-343-8448 FAX, www.tgen.org

Sharon A. Savage, M.D., F.A.A.P.,

Senior Investigator, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr., Rm. 6E454, MSC 9772, Bethesda, MD 20850-9772, Tel: 240-276-7241. Fax: 240-276-7836. savagesh@mail.nih.gov

Lisa Mirabello, Ph.D., M.S.,

Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 6E422, Bethesda, MD 20850-9772, mirabellol@mail.nih.gov

Denise Reinke, MS, NP, MBA,

President, SARC, 24 Frank Lloyd Wright Drive, PO Box 406, Ann Arbor, MI 48105, Lobby A Suite 3100, Phone: 734-930-7600, Fax: 734-930-7557

Donald A. Barkauskas, Ph.D.,

Statistician, QuadW-COG Childhood Sarcoma Biostatistics and Annotation Office, Children's Oncology Group, 222 East Huntington Drive, Suite 100, Monrovia, CA 91016-8012, Phone: (626) 241-1540, Fax: (626) 445-4334, DBarkauskas@childrensoncologygroup.org

Mark Krailo, Ph. D.,

Department of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, 90033, mkrailo@childrensoncologygroup.org

Malcolm A. Smith, MD, PhD, and

National Cancer Institute, 9609 Medical Center Drive, RM 5-W414, MSC 9737, Bethesda, MD 20892 (for U.S. Postal Service Delivery), Rockville, MD 20850 (for non-USPS courier delivery and campus visits), Phone: (240) 276-6087, FAX: (240) 276-7892, Malcolm.Smith@nih.gov

Mark Bernstein, MD, FRCPC

Dept. of Pediatrics, IWK Health Center, Dalhousie University, 5850/5980 University Avenue, Halifax, NS, Canada, B3K 6R8

Abstract

Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be the most common cause of mortality in osteosarcoma patients. A conventional drug development path requiring drugs to induce regression of established lesions has not led to improvements for osteosarcoma patients in over 30 years. Based on our growing understanding of metastasis biology, it is now reasonable and essential that we focus on developing therapeutics that target metastatic progression. To advance this agenda a meeting of key opinion leaders and experts in the metastasis and osteosarcoma communities was convened in Bethesda Maryland. The goal of this meeting was to provide a "Perspective" that would establish a preclinical translational path that could support the early evaluation of potential therapeutic agents that uniquely target the metastatic phenotype. Although focused on osteosarcoma the need for this perspective is shared among many cancer types. The consensus achieved from the meeting included the following: That the biology of metastatic progression is associated with metastasis-specific targets/processes that may not influence grossly detectable lesions; targeting of metastasis-specific processes is feasible; rigorous preclinical data is needed to support translation of metastasis-specific agents into human trials where regression of measurable disease is not an expected outcome; preclinical data should include an understanding of mechanism of action, validation of pharmacodynamic markers of effective exposure and response, the use of several murine models of effectiveness, and where feasible the inclusion of the dog with naturally occurring osteosarcoma to define the activity of new drugs in the micro-metastatic disease setting.

Introduction

As is the case for many solid tumors, the problem of metastasis is the most important cause of morbidity and mortality in osteosarcoma patients. Based on historical data, over 80% of patients will progress to develop metastasis following resection of the primary tumor alone, and even with the addition of chemotherapy to primary tumor resection, approximately one-third of patients presenting with localized disease will subsequently develop pulmonary

metastases (1, 2). Long-term outcomes for osteosarcoma patients with either localized or metastatic disease have not substantively improved in over 30 years, however progress in our understanding of metastasis biology now offers hope to address this unmet clinical need. Recent studies have defined the existence of druggable targets linked to metastatic progression of cancer (3-7). Many of these targets and associated processes appear to specifically influence the progression of metastatic cells from microscopic disease to that of grossly detectable lesions (8). The modulation of these targets using either genetic or pharmacological approaches may have no measurable effect on established and grossly detectable lesions at either the primary or metastatic locations (9, 10). As such these agents are predicted to fail in conventional early phase human trials that require regression of established disease (8, 11). Preclinical therapeutic studies in a variety of cancer histologies now support this prediction; novel therapeutic agents designed from an understanding of the unique vulnerabilities and targets linked to metastatic progression are indeed active against metastatic progression but may have no activity in the setting of measurable disease (12-14). In order for novel agents that target metastatic progression to advance, clinical trials conducted in the adjuvant setting, in the absence of measurable disease, will be required early in the drug development path. As noted above, our past reliance and requirement for regression of measurable lesions to advance therapeutic agents in drug development for osteosarcoma has not been rewarding. Accordingly, rigorous preclinical data will be necessary to support the evaluation of a drug whose activity and therapeutic benefit may be limited to preventing progression of existent microscopic disease, without the expectation of measurable anticancer activity in conventional response-based clinical trials. To advance the development of such novel therapeutics, a meeting of key opinion leaders and experts in the fields of bone sarcoma biology, metastasis, preclinical cancer drug development (including cancer biologists and veterinary oncologists), and the clinical management of osteosarcoma patients (pediatric oncologists, medical oncologists, radiation oncologists, and surgeons) was convened in Bethesda Maryland on April 6th, 2013, with the support of the QuadW Foundation, the Children's Oncology Group, and CureSearch. The goal of this meeting was to establish a consensus "Perspective" on osteosarcoma drug development, which would focus on the problem of metastasis and establish a consistent translational path that could support the early evaluation of potential therapeutic agents that uniquely target the metastatic phenotype.

Osteosarcoma Drug Development Infrastructure

With the overriding goal of improving long-term outcomes for patients, the osteosarcoma community has initiated or participated in programs that can now support the development and integration of novel agents into osteosarcoma therapy. First, through the efforts of the QuadW - Children's Oncology Group Childhood Sarcoma Biostatistics and Annotation Office (CSBAO), a robust and clinically annotated osteosarcoma biospecimen repository is now available to fuel biological investigations (J. Glover Personal Communication; ASCO 2013 Abstract). This repository has been linked to a relational database that will be progressively annotated with biological analyses performed on these tissues thereby allowing for the first time *in silico* analysis in this disease. Second, the NCI TARGET (Therapeutically Applicable Research to Generate Effective Treatments) initiative is

expected to deliver a greater understanding of osteosarcoma genomic targets that may be matched with existing or novel cancer therapeutics (<http://ocg.cancer.gov/programs/target>). Third, the Pediatric Preclinical Testing Program (PPTP) has an established infrastructure to test novel agents for their activity against primary tumor growth in a diverse set of osteosarcoma xenograft models (<http://pptp.nchresearch.org/>) (15). Finally, the NCI Comparative Oncology Program has established a preclinical and translational consortium (COTC) that can rapidly evaluate the therapeutic value of novel agents in pet dogs that have naturally developed cancers most notably including osteosarcoma (<https://ccrod.cancer.gov>) (16). With progress on these fronts, it is now feasible to integrate advances in our understanding of osteosarcoma and metastasis biology with preclinical and translational studies as a means to prioritize agents for evaluation in patients. It is recognized that in order for the successful implementation of this integrative approach, several existing drug development approaches, perspectives and resources will need to be re-focused on the problem of metastatic progression rather than regression of measurable cancer lesions alone.

The Quagmire for Osteosarcoma Metastasis Drug Development

The process of metastasis in osteosarcoma patients appears similar to patients with other solid tumors. The steps associated with the metastatic spread of cancer cells from a primary tumor to a distant secondary site involve a complex set of discrete processes that are in many ways distinct from those associated with primary tumor growth (17-23). Most metastasis biology studies suggest that cancer cells readily gain entry to the circulation from the primary tumor and that the majority of circulating cancer cells successfully arrive and extravasate at the distant secondary site; however, only a small minority of cells are able to survive at the distant and foreign microenvironment. Indeed, managing this critical stage of vulnerability is a defining feature of metastatic cells (24). Through a combination of selective and acquired events involving both genetic and epigenetic processes, metastatic cells are distinguished from non-metastatic cells and are able to accommodate and adapt to the stresses incurred during metastatic progression (25). In some cases the same oncogenic events linked to primary tumor formation and maintenance are also responsible for facets of the metastatic cascade; whereas other events are likely more intrinsically linked to the unique features of metastatic biology provided by metastasis specific genes and gene regulation (26, 27). As such there are unique targets and processes (often druggable) that may drive the progression of existent microscopic metastatic cells to grossly detectable lesions.

There are now sufficient experimental data to believe that the progression of single metastatic cells to established lesions occurs after patients present with apparently localized disease and continues after the development of radiographically detectable lesions. First, it is likely that those cells that are able to complete the steps of the metastatic cascade will subsequently metastasize to other parts of the same secondary organ or to distinct secondary sites late in clinical presentation (20, 28, 29). Second, it is reasonable that tumor cells remain dormant as quiescent single cells for long periods of time before they establish colonies of micrometastases in which a balance of proliferation and apoptosis exists, and before they progress to detectable lesions (19, 30, 31). Finally, it remains unclear if this period of metastatic dormancy occurs at the secondary site (*i.e.*, in the lung in the case of

osteosarcoma) or in a so-called sanctuary sites (*i.e.*, the bone marrow) with subsequent and therefore late spread to the eventual clinical secondary site (32-35). Accordingly, it is reasonable that targeting metastatic progression, particularly at the secondary site will provide clinical benefit to patients in all stages of presentation (*i.e.*, it is not too late to target the metastatic cascade even after a patient develops metastasis).

Recognizing the imperative to assess new therapeutic agents that target the metastatic phenotype, a consensus on the nature of preclinical data needed to advance the clinical development of an anti-metastatic agent is necessary. As this necessary translation is planned, it is important to recognize that decisions to advance a therapeutic agent to clinical development in the adjuvant-setting may need to be made without any prior evidence of anti-tumor activity in human patients. As outlined above, using input from experts in the field we now propose a consensus “Perspective” towards this preclinical to clinical translational drug development challenge (Table 1). An important outcome of having a consensus on the types of data that are determined to be valuable, as a novel agent is proposed for translation, is that preclinical investigators will have a clear sense of what may be expected and similarly that translational groups will be clear on what they may expect as they evaluate and review therapeutic agents for potential clinical development. In addition to providing a clear consensus on the types of data that may be useful for translation of agents that target metastasis, Table 1 also provides a mechanism to compare or prioritize agents based on these data. Importantly, Table 1 is not intended to prescribe “go” or “no go” decisions on the suitability of potential agents, but rather serves to provide a consistent framework to objectively value and ascribe quantifiable merit to a list of novel agents being considered for translational assessment. In Table 1, vertical columns represent discrete translational data types that may be available for consideration in the preclinical to clinical translation of a novel therapy that targets metastasis. Within each column, a Progressive Merit Score (PM Score) is assigned an integer value between 1 and 6, commensurate with the potential “value” of the data in that category. Similarly across columns, a Relative Merit Score (RM Score) across data types is assigned an integer value between 1 and 3, and commensurate with our perceived “value” of that data-type to this drug development question. Using the PM Score (within a Data Type) and the RM Score (across Data Types), their product (PM Score \times RM Score) is used to generate a Cumulative Relative Dataset Merit Score which then can be assigned and compared among distinct data-sets for a specific translational therapeutic opportunity. The guidance provided in Table 1 will provide a collective understanding of the necessary and optimal data set needed to advance therapeutic agents with activity against the metastatic phenotype and in-so-doing, will help prioritize those agents for clinical development in patients with osteosarcoma.

As outlined above the pattern of failure for osteosarcoma patients continues to involve the predictable development of metastasis to the lungs despite effective and complete control of the primary tumor. Despite attempts to intensify therapy, there has been a failure to decrease the development of metastasis and improve patient survival over the past 30 years. As such there are no recent “historical controls” that can be used as positive “controls” to assess the scoring system. Accordingly validation of the proposed approach will require prospective studies of novel therapeutic agents that are first evaluated through the proposed scoring

system, that then move on to human clinical trials. The recent endorsement of the details outlined in this manuscript by the National Cancer Institute Pediatric and Adolescent Solid Tumor Steering Committee (PASTSC) will serve as a starting point for future discussions which will lead to the potential integration of the proposed scoring system for the prioritization of novel agents planned for clinical evaluation in pediatric osteosarcoma patients. Accordingly, there will be an opportunity over time to test, validate and modify the scoring system prospectively. As a means to demonstrate the feasibility and future use of the scoring system, Table 2 provides examples for how the scoring system can be applied, in this case by using therapeutic agents that have been recently evaluated in osteosarcoma patients. These agents include liposomal muramyl-tripeptide phosphatidyl-ethanolamine (L-MTP-PE) and inhaled granulocyte-colony stimulating factor (GM-CSF), (36-38). Based on supportive preclinical data and phase II trials in osteosarcoma, L-MTP-PE was advanced to a phase III trial in osteosarcoma. The study included a factorial design using event free survival (EFS). No improvement in EFS was seen within this factorial design; however, a subsequent post-hoc analysis revealed an 8% improvement in survival in patients (36). All results, including the post-hoc analysis of survival, were interpreted to be supportive of substantial evidence of effectiveness by the European Medicine Agency and led to the recent approval of this agent in Europe for patients with osteosarcoma. With a focus on the primary study endpoint of EFS, the US Food and Drug Administration did not interpret the data to be supportive of substantial evidence for effectiveness and the drug was not approved. The score for L-MTP-PE, using our described scoring system (Cumulative Relative Dataset Merit), was 60. In the case of the second example, inhaled GM-CSF was advanced into a trial of first lung relapse osteosarcoma patients based on evidence supportive of the feasibility of inhaled cytokine therapy. In the first lung relapse population and within the constraints of the executed trial there was no evidence immune modulation or antimetastatic activity demonstrated in patients (37). The Cumulative Relative Dataset Merit score for GM-CSF was 26. Based on the two examples presented above it is clear that a broad range in scores will be derived from the proposed scoring method. Indeed, it is reasonable that these broad scoring possibilities will allow the prioritization of novel agents and allow the hypothesis suggested by the proposed scoring method to be testable over time.

A Proposed Mechanism to Value and Prioritize Preclinical and Translational Drug Development Data (Table 1)

Target biology and expression

The most valuable drug targets, as they relate to the problem of metastatic progression are those with functions that are fundamentally linked to the pathogenesis of micrometastatic progression. It is optimal for these targets to be expressed in micrometastatic cells. Although there are initial targets that have been identified with these credentials, additional studies are needed to expand the list of potential target candidates. Tissues from metastatic lesions and matched primary tumor tissues from the same patients are not widely available at this time and would provide a broader understanding of target expression profiles and their dynamics during metastatic progression. Expanding existing biospecimen efforts to collect clinically annotated tissues throughout the course of disease presentation and progression is required in order to better understand the development of metastases in osteosarcoma.

Drug mechanism of action and pharmacodynamics

It is likely that a more detailed understanding of mechanism of action (MOA), and associated pharmacodynamic markers of effective therapeutic exposure and target modulation in tumor and surrogate tissues will be needed for agents that target metastasis and metastatic progression compared to agents that may act on measurable disease. Since it is not likely that toxicity will be a primary determinant of dose selection with biologically defined therapeutics, an understanding of MOA and pharmacodynamics may be critical in the definition of drug dose and schedule. Furthermore, it is widely recognized that the complexity of the metastatic cascade is difficult to model *in vitro*, as such the use of multiple (distinct) *in vitro* or preferably *ex vivo* assays (*i.e.*, Pulmonary Metastasis Assay; PuMA; (39)) of metastasis should be considered for defining early evidence of therapeutic activity and more importantly to elucidate mechanisms of action for a metastasis-targeting therapeutic.

Preclinical and murine models

Data demonstrating the activity of a novel therapeutic agent, at pharmacologically achievable exposures in several distinct murine cancer models is considered important for the development of all cancer drugs. The use of experimental metastasis models (tail vein injection) that result in the seeding of lung with cancer cells are valuable to “screen” potential therapeutics, however, the use of orthotopic models of osteosarcoma that include surgical management of the primary tumor and spontaneous pulmonary metastasis should be prioritized as a means to more fully demonstrate the value of a therapeutic approach. Genetically engineered models of osteosarcoma have now been described and may be used in drug evaluation (15, 40). Genetically engineered and other syngeneic models will be essential for therapeutics that modulate the immune response as part of their mechanisms of action. It is understood that the magnitude of a therapeutic response will be part of the basis to prioritize one therapeutic outcome against another. As such, it is essential that the variables that influence the behavior of a model and therefore the magnitude of potential responses are considered (*i.e.*, delivered cell number, background of the mouse strain used, time of treatment initiation) when comparisons between studies (and between therapeutic agents) are made.

Canine osteosarcoma

Beyond the well-recognized difficulties with drug development in osteosarcoma an important opportunity has been delivered by nature through the spontaneous development of osteosarcoma in pet dogs (41). The opportunities of this comparative approach to cancer drug development have been reviewed elsewhere (42). Biological, histological and genomic features of osteosarcoma in dogs and humans are highly similar and have provided a basis to evaluate novel therapeutics in dogs with osteosarcoma (43, 44). As part of the broader field of comparative oncology, translational drug development studies in dogs with osteosarcoma have been used to define dose and schedule for therapeutic agents through rigorous pharmacokinetic-pharmacodynamic endpoints that can involve serial biopsies of tumor and collection of biological materials (*i.e.*, normal tissue surrogates) before and after exposure to a novel therapeutic (16, 45). Modeling of such dose-finding studies for agents that target

metastasis may be an important use of the dog as a model. However the greatest value of the dog with osteosarcoma as it relates to this “Perspective” is the opportunity to conduct studies in the setting of micrometastatic disease. In such studies dogs will undergo management of the primary tumor and then in the adjuvant setting receive investigational agents alone or in combination with conventional chemotherapy backbones that are similar to those used in human patients. Through the integration of imaging endpoints, metastasis-free interval or survival may then be used to evaluate and compare different doses and schedules of investigational agents. Through the availability of a multi-center consortium of veterinary centers led by the National Cancer Institute (Comparative Oncology Trials Consortium - (<https://ccrod.cancer.gov>)) and the high prevalence of osteosarcoma in dogs, multiple studies (or study arms) may be successfully accrued in a time period that would allow comparison and prioritization of agents for evaluation in human patients. It is likely that observed activity in the adjuvant setting in the dog model would provide the most compelling data for the value of a novel therapeutic that may target metastatic progression.

Pharmacokinetics

The nature and type of pharmacokinetic data needed to advance an agent that targets metastatic progression is not likely to be different from conventional cancer therapeutics. In the preclinical setting, studies should be conducted at exposures that are likely to be achieved in human patients. It is reasonable that studies of distinct treatment regimens (dose-schedule) in patients may be important to optimize therapeutic responses in the adjuvant settings. It is also important that these exposures are safely maintained during what may be extended treatment intervals (*i.e.*, during the period of minimal residual disease).

Human clinical data

For agents that target micrometastatic progression, early human clinical trials will continue to focus on tolerability. As part of the safety assessment of these agents their use in the setting of a conventional osteosarcoma backbone (*i.e.*, methotrexate, doxorubicin and cisplatin) will need to be established. Furthermore, as noted above, it is reasonable that the duration of assessment of tolerability will need to be extended given the expectation that novel agents that target metastatic progression may require prolonged treatment exposures. As described under pharmacodynamics, given the likely absence of response in a measurable tumor, early phase human trials should optimally include pharmacodynamic endpoints that will provide confidence on the adequacy of exposure and of the potential effectiveness of the exposure in accessible biospecimens. Unlike many other cancer histologies, clinical trials that assess the activity of therapeutic agents against metastatic progression have been successfully completed and are currently underway in osteosarcoma patients. These trials including the evaluation of MTP-PE (46), GM-CSF (47), and a src tyrosine kinase (SARC012; <http://sarctrials.org/Open-SARC-Trials>) inhibitor were possible given the unique pattern of metastatic progression in osteosarcoma patients that includes the lung as a target organ and the fact that surgical resection of metastases is considered to be part of the standard of care. As novel trial designs are considered there is a need to prioritize longitudinal endpoints of survival and metastasis-free interval and to ensure that accrual and completion of studies can occur in a reasonable time based on careful consideration of

eligibility criteria and inclusion of multiple partners including both pediatric and adult oncology (9).

Conclusion

Improvements in long-term outcomes for osteosarcoma patients require a drug development path that prioritizes agents with activity against metastatic progression and not necessarily regression of measurable lesions alone. This approach may also improve outcome for patients with more common cancers too. The successful development of such agents demands a rigorous preclinical data set, since we may not rely on early human clinical trials of tumor regression to support the development of these potentially valuable therapeutic agents. This “Perspective” provides reasonable guidance to consider and prioritize such preclinical data in osteosarcoma. The use of these guidelines will assist investigators in conducting studies that are believed to be most valuable in the assessment of agents that uniquely target metastatic progression. Similarly the use of these guidelines will allow more consistent evaluation and comparison of potentially active agents as they are considered for clinical translation. It is reasonable that after sufficient experience is gained through the use of these guidelines that improvements and refinements can be made so as to optimize the preclinical and translational development of drugs in osteosarcoma.

Acknowledgments

This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Research is supported by the Chair’s Grant U10 CA98543 and Human Specimen Banking Grant U24 CA114766 of the Children’s Oncology Group from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Additional support for research is provided by a grant from the WWW (QuadW) Foundation, Inc. (www.QuadW.org) to the Children’s Oncology Group.

References

1. Janeway, K.; Gorlick, R.; Bernstein, M. Osteosarcoma. In: Orkin, SH.; Fisher, DE.; Look, AT.; Lux, S.; Ginsburg, D.; Nathan, DG., editors. *Oncology of Infancy and Childhood*. Saunders Elsevier; Philadelphia, PA: 2009. p. 871-910.
2. Marina, N.; Gorlick, R.; Bielack, S. Pediatric Osteosarcoma. In: Carroll, W.; Finlay, J., editors. *Cancer in Children and Adolescents*. Jones and Bartlett; Sudbury, MA: 2010. p. 383-394.
3. Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M, et al. Breast cancer metastasis: issues for the personalization of its prevention and treatment. *Am J Pathol*. 2013; 183(4): 1084–95. [PubMed: 23895915]
4. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. *Nat Rev Cancer*. 2011; 11(5):352–63. [PubMed: 21472002]
5. Christofori G. New signals from the invasive front. *Nature*. 2006; 441(7092):444–50. [PubMed: 16724056]
6. Iizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. *Biochim Biophys Acta*. 2008; 1786(2):87–104. [PubMed: 18692117]
7. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature*. 2012; 485(7396):55–61. [PubMed: 22367541]
8. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. *Cancer Treat Rev*. 2010; 36(2):177–84. [PubMed: 20015594]
9. Steeg PS. Perspective: The right trials. *Nature*. 2012; 485(7400):S58–9. [PubMed: 22648501]

10. Heikenwalder M, Borsig L. Pathways of metastasizing intestinal cancer cells revealed: how will fighting metastases at the site of cancer cell arrest affect drug development? *Future Oncol.* 2013; 9(1):1–4. [PubMed: 23252556]
11. Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. *Eur J Cancer.* 2010; 46(7):1177–80. [PubMed: 20307970]
12. Rao B, Han M, Wang L, Gao X, Huang J, Huang M, et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. *J Transl Med.* 2011; 9:17. [PubMed: 21272332]
13. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. *Oncogene.* 2012; 31(3): 269–81. [PubMed: 21706056]
14. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. *J Natl Cancer Inst.* 2008; 100(15): 1092–103. [PubMed: 18664652]
15. Sampson VB, Gorlick R, Kamara D, Anders Kolb E. A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. *Front Oncol.* 2013; 3:132. [PubMed: 23755370]
16. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. *PLoS One.* 2009; 4(3):e4972. [PubMed: 19330034]
17. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. *Am J Pathol.* 1998; 153(3):865–73. [PubMed: 9736035]
18. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. *Lancet.* 2007; 369(9574):1742–57. [PubMed: 17512859]
19. Rice J. Metastasis: The rude awakening. *Nature.* 2012; 485(7400):S55–7. [PubMed: 22648500]
20. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. *Cell.* 2009; 139(7):1315–26. [PubMed: 20064377]
21. Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. *Cancer Res.* 2006; 66(23):11089–93. [PubMed: 17145848]
22. Hoon DS, Kitago M, Kim J, Mori T, Piris A, Szyfelbein K, et al. Molecular mechanisms of metastasis. *Cancer Metastasis Rev.* 2006; 25(2):203–20. [PubMed: 16770533]
23. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. *Nat Med.* 2010; 16(1):116–22. [PubMed: 20023634]
24. Chambers AF, Naumov GN, Varghese HJ, Nadkarni KV, MacDonald IC, Groom AC. Critical steps in hematogenous metastasis: an overview. *Surg Oncol Clin N Am.* 2001; 10(2):243–55. vii. [PubMed: 11382585]
25. Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. *Int J Biochem Cell Biol.* 2009; 41(7):1452–62. [PubMed: 19401145]
26. Shoushtari AN, Szmulewitz RZ, Rinker-Schaeffer CW. Metastasis-suppressor genes in clinical practice: lost in translation? *Nat Rev Clin Oncol.* 2011; 8(6):333–42. [PubMed: 21522123]
27. Rinker-Schaeffer CW, Welch DR, Sokoloff M. Defining the biologic role of genes that regulate prostate cancer metastasis. *Curr Opin Urol.* 2000; 10(5):397–401. [PubMed: 11005442]
28. Sugarbaker EV, Cohen AM, Ketcham AS. Do metastases metastasize? *Ann Surg.* 1971; 174(2): 161–6. [PubMed: 5560840]
29. Tait CR, Dodwell D, Horgan K. Do metastases metastasize? *J Pathol.* 2004; 203(1):515–8. [PubMed: 15095473]
30. Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. *Clin Cancer Res.* 2012; 18(3):645–53. [PubMed: 22156560]
31. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoehorhoff MJ, et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. *Cancer Res.* 2008; 68(15):6241–50. [PubMed: 18676848]

32. Sanger N, Effenberger KE, Riethdorf S, Van Haasteren V, Gauwerky J, Wiegatz I, et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. *Int J Cancer*. 2011; 129(10):2522–6. [PubMed: 21207426]
33. Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS. Mechanisms of cancer cell metastasis to the bone: a multistep process. *Future Oncol*. 2011; 7(11):1285–97. [PubMed: 22044203]
34. Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. *Clin Cancer Res*. 2011; 17(17):5553–8. [PubMed: 21676926]
35. Bruland OS, Hoifodt H, Hall KS, Smeland S, Fodstad O. Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients. *Cancer Treat Res*. 2009; 152:509–15. [PubMed: 20213412]
36. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. *J Clin Oncol*. 2008; 26(4):633–8. [PubMed: 18235123]
37. Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. *Clin Cancer Res*. 2010; 16(15):4024–30. [PubMed: 20576718]
38. Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, et al. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. *Cancer Med*. 2012; 1(2):207–17. [PubMed: 23342270]
39. Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J, et al. Modeling metastasis biology and therapy in real time in the mouse lung. *J Clin Invest*. 2010; 120(8):2979–88. [PubMed: 20644255]
40. Ng AJ, Mutsaers AJ, Baker EK, Walkley CR. Genetically engineered mouse models and human osteosarcoma. *Clin Sarcoma Res*. 2012; 2(1):19. [PubMed: 23036272]
41. Withrow SJ, Wilkins RM. Cross talk from pets to people: translational osteosarcoma treatments. *ILAR J*. 2010; 51(3):208–13. [PubMed: 21131721]
42. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. *Nat Rev Cancer*. 2008; 8(2):147–56. [PubMed: 18202698]
43. Withrow SJ, Khanna C. Bridging the gap between experimental animals and humans in osteosarcoma. *Cancer Treat Res*. 2009; 152:439–46. [PubMed: 20213406]
44. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. *BMC Genomics*. 2009; 10:625. [PubMed: 20028558]
45. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. *Cancer Invest*. 2000; 18(8):781–92. [PubMed: 11107448]
46. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. *Am J Clin Oncol*. 1995; 18(2):93–9. [PubMed: 7900714]
47. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. *Clin Cancer Res*. 1999; 5(9):2316–23. [PubMed: 10499599]
48. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. *Clin Cancer Res*. 2011; 17(8):2110–9. [PubMed: 21372215]
49. Hisano G, Fidler IJ. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. *Cancer Immunol Immunother*. 1982; 14(2):61–6. [PubMed: 6965228]
50. Maeda M, Knowles RD, Kleinerman ES. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. *Cancer Commun*. 1991; 3(10-11):313–21. [PubMed: 1722107]

51. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. *Cancer Res.* 1989; 49(16):4665–70. [PubMed: 2787207]
52. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. *Cancer Res.* 1983; 43(5):2010–4. [PubMed: 6831430]
53. LeGrue SJ, Saiki I, Romerdahl CA, Fidler IJ. Systemic macrophage activation by liposomes containing MTP-PE in mice immunosuppressed with cyclosporine. *Transplantation.* 1987; 43(4): 584–6. [PubMed: 3576675]
54. Fidler IJ, Fan D, Ichinose Y. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma. *Invasion Metastasis.* 1989; 9(2):75–88. [PubMed: 2496047]
55. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. *J Natl Cancer Inst.* 1989; 81(12):935–8. [PubMed: 2733037]
56. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. *Clin Cancer Res.* 1995; 1(12):1595–601. [PubMed: 9815961]
57. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. *J Clin Oncol.* 1992; 10(8):1310–6. [PubMed: 1634921]
58. Landmann R, Obrist R, Denz H, Ludwig C, Frost H, Wesp M, et al. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. *Biotherapy.* 1993; 7(1):1–12. [PubMed: 8068481]
59. Anderson PM, Meyers P, Kleinerman E, Venkatakrisnan K, Hughes DP, Herzog C, et al. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. *Pediatr Blood Cancer.* 2014; 61(2): 238–44. [PubMed: 23997016]
60. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. *J Clin Oncol.* 1989; 7(12):1915–25. [PubMed: 2479721]
61. Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). *Cancer Immunol Immunother.* 1992; 34(4):211–20. [PubMed: 1537053]
62. Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. *J Immunother Emphasis Tumor Immunol.* 1995; 17(3):181–93. [PubMed: 7613644]
63. Markovic SN, Suman VJ, Nevala WK, Geeraerts L, Creagan ET, Erickson LA, et al. A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. *Am J Clin Oncol.* 2008; 31(6):573–9. [PubMed: 19060590]

Statement of Translational Relevance

A focus on drug development that targets metastatic progression and not necessarily regression of measurable lesions is needed to improve the stagnant long-term outcomes for osteosarcoma patients. Through the input of key opinion leaders in the fields of metastases biology and osteosarcoma, the following “Perspective” represents a consensus on the relative value and priorities of a preclinical data set that would support the translation of a novel therapeutic towards clinical development in osteosarcoma patients. Such a metastasis-focused and rigorous preclinical data set is needed for such translation since we may not be able to rely on early human clinical trials of tumor regression to support the development of these potentially valuable therapeutic agents.

Table 1
Assessment of Data Set Supporting the Preclinical to Clinical Translation of a Novel Therapeutic Targeting Osteosarcoma Metastasis

Translational Data Types ^a		Target modulation (Pharmacodynamics)	Murine Models	Canine Osteosarcoma Models	Pharmacokinetics	Human Clinical Data	Progressive Merit Score within a Data Type ^b
Osteosarcoma Target/Process Biology and Expression	Drug Mechanism of Action and Pharmacodynamics	Target modulation (Pharmacodynamics)	Murine Models	Canine Osteosarcoma Models	Pharmacokinetics	Human Clinical Data	Progressive Merit Score within a Data Type ^b
Expression in cancer cell lines; not necessarily osteosarcoma	Drug and target biology linked to metastatic phenotype - Demonstrated in multiple <i>in vitro</i> models	Target modulation demonstrated in relevant tissues/cells at achievable exposures	Evaluation of activity against primary tumor progression (agent may or may not have activity in this setting)	Target expression or biology understood and similar to human disease	Exposures believed to be active in model systems are achievable in patients	Complete phase I study that includes relevant exposure duration (does not need to be pediatric)	1
Expressed at the protein level in osteosarcoma			Demonstration of significant activity against experimental (tail vein) metastasis for any cancer histology		Optimal dose and schedule in relevant patient population has demonstrated	Safety of new agent demonstrated in combination with MAP (or similar) chemotherapy	2
Target or process expressed or active in reasonable proportion of osteosarcoma patients			Demonstration of significant activity against one orthotopic spontaneous metastasis model of any cancer histology	In dogs with micrometastatic disease, demonstration of single agent activity > 8 months; or > 24 months in combination with cytotoxic chemotherapy			3
Expressed in osteosarcoma micrometastasis	Activity of agent demonstrated in complex models more reflective of metastasis (i.e., (PuMA) ^d or renal capsule invasion assay)	Target modulation demonstrated in relevant tissues/cells at achievable exposures	For immunologically-based agents: Evaluation in more than one syngeneic or GEM model of any cancer histology		PK, dose and schedule in combination with chemotherapy similar to MAP has been demonstrated		4
Target or process is abundantly present or active in metastatic osteosarcoma samples	Clear biologic rationale for activity specific for osteosarcoma	Target modulation linked to mechanism of action	Demonstration of significant activity against more than one orthotopic				5

Translational Data Types ^a							
Osteosarcoma Target/Process Biology and Expression	Drug Mechanism of Action and Pharmacodynamics	Target modulation (Pharmacodynamics)	Murine Models	Canine Osteosarcoma Models	Pharmacokinetics	Human Clinical Data	Progressive Merit Score within a Data Type ^b
			spontaneous, syngeneic, or GEM metastasis model (including at least one osteosarcoma model)				
	Activity against metastasis demonstrated in a multiple <i>in vitro</i> models ^e	Target modulation in surrogate tissue appropriate for translation and therapeutic monitoring	Evaluation against metastatic progression in models derived from chemo-resistant or metastatic osteosarcoma patients	Demonstration >50% improvement in EFS in dogs with micrometastatic osteosarcoma in a randomized placebo-controlled study design		Clinical activity against micrometastatic progression demonstrated in any human cancer OR clinical activity against osteosarcoma	6
Relative Merit Across Data Types^c	1	2	2	3	1	3	Cumulative Relative Dataset Merit - Relative Merit × Data Type Merit ^f

^aTranslational Date Type: Describes various types of data that will be collectively considered in the preclinical to clinical translation of a novel therapy that targets osteosarcoma metastasis.

^bProgressive Merit within a Data Type: Scores from 1 to 6 will be applied to “value” the types of data provided within each Data-Type. For example, Under the Data-type of “Osteosarcoma Target Biology/Expression”, the “expression of [a target] in cancer cell lines” is not viewed to be as valuable (Progressive Merit Score of 1), compared to the “Target is abundantly present in osteosarcoma samples, or drug target is fundamental in osteosarcoma pathogenesis” (Progressive Merit Score of 6).

^cRelative Merit Across Data Types: Scores from 1 to 3 have been applied to each Data-Type. Based on the presented assignments, data from “Murine Models” has a greater Relative Merit (Score =2) than “Osteosarcoma Target Biology/Expression” (Score = 1). It is understood that there may be novel drugs that do not have a data set that includes all types of listed Translational Data.

^d*Ex vivo* Pulmonary Metastasis Assay (PuMA)

^eExample *in vitro* models including scratch assay, Boyden chamber, cell adhesion assays, etc.

^fUsing the Progressive Merit Score (within a Data Type) and the Relative Merit Across Data Types, a Cumulative Relative Dataset Merit can be determined and compared between distinct translational therapeutic opportunities.

Example: Determination of the Cumulative Relative Dataset Merit of a novel therapeutic for osteosarcoma translation

Data Set Type	Description of Data	Progressive Merit within a Data Type	Relative Merit Across Data Types	Cumulative Relative Dataset Merit
Target Biology/Expression	Expression in micrometastasis	4	1	4
Murine Models	Demonstration of significant activity against experimental	2	2	4
Canine Models	In dogs with micrometastatic disease, demonstration of single agent activity > 8	3	3	9
Human Clinical Data	Evaluation of optimal dose and schedule in relevant	4	3	12
Total Cumulative Relative Dataset Merit				29

Table 2
Use Examples for the Cumulative Relative Dataset Merit of Agents Recently Evaluated or In Study in Osteosarcoma Patients

Determination of the Cumulative Relative Dataset Merit of MTP-PE in Osteosarcoma.						
Data Set Type	Description of Data	Progressive Merit within a Data Type	Relative Merit Across Data Types	Cummulative Relative Dataset Mert	Supporting References	
Target Biology/Expression	Target is abundantly present in metastatic osteosarcoma samples	5	1	5	49	
Drug Mechanism of action and Pharmacodynamics	Clear biologic rationale for activity specific for osteosarcoma	5	1	5	50,51	
Target Modulation/Pharmacokinetics	Target modulation linked to mechanism of action	5	2	10	52,53,54	
Murine Models	Demonstration of significant activity against one orthotopic spontaneous metastasis model	3	2	6	55	
Canine Models	Demonstration >50% improvement in EFS in dogs with micrometastatic osteosarcoma in a randomized placebo-controlled study design	6	3	18	56,57	
Pharmacokinetics	Evaluation of optimal dose and schedule in relevant patient population	4	1	4	58,59,60	
Human Clinical Data	Safety of new agent demonstrated in combination with MAP (or similar) chemotherapy	4	3	12	61, 62	
Total Cummulative Relative Dataset Merit				60		
Determination of the Cumulative Relative Dataset Merit of Aerosol GM-CSF in Osteosarcoma.						
Data Set Type	Description of Data	Progressive Merit within a Data Type	Relative Merit Across Data Types	Cummulative Relative Dataset Mert	Supporting References	
Target Biology/Expression	Expression in micrometastasis	5	1	5	49	
Drug Mechanism of action and Pharmacodynamics	Drug and target biology linked to metastatic phenotype - Demonstrated in multiple <i>in vitro</i> models	1	1	1		
Target Modulation/Pharmacokinetics		0	0	0		
Murine Models		0	0	0		
Canine Models		0	0	0		
Pharmacokinetics	Optimal dose and schedule in relevant patient population has demonstrated	2	1	2	63	
Human Clinical Data	Evaluation of optimal dose and schedule in relevant patient population	6	3	18	48,37	

Determination of the Cumulative Relative Dataset Merit of Aerosol GM-CSF in Osteosarcoma.

Data Set Type	Description of Data	Progressive Merit within a Data Type	Relative Merit Across Data Types	Cumulative Relative Dataset Mert	Supporting References
Total Cumulative Relative Dataset Merit					
				26	